These days there is a lot of hype surrounding the use of artificial intelligence (AI) in data-driven drug development. The advances are incredible, and wide-spread, but how much of the information is valid? It’s time to separate fact from fiction, identify some of the issues surrounding the status quo of medical technology, and outline some solutions for the future.
To begin, it’s of paramount importance to recognize humanity, and to recognize what is really at stake here, and the reason we use AI in the first place. Which is to find ways to help people by using all the science and technology at our disposal. So if people are important, if our humanity is a priority, we need a holistic understanding of the state of the industry. We are not debating the use of AI to advance science, but identifying the line between hypothesis-driven and data-driven development.
L'IA : opportunité ou menace ? Les DSI de la finance s'interrogent Alors que l'intelligence…
Sécurité des identités : un pilier essentiel pour la conformité au règlement DORA dans le…
La transformation numérique du secteur financier n'a pas que du bon : elle augmente aussi…
Telegram envisage de quitter la France : le chiffrement de bout en bout au cœur…
L'intelligence artificielle (IA) révolutionne le paysage de la cybersécurité, mais pas toujours dans le bon…
TISAX® et ISO 27001 sont toutes deux des normes dédiées à la sécurité de l’information. Bien qu’elles aient…
This website uses cookies.